Skip to content
Triangle logo TriangleGet started
← Study library

NCT01775475 · REGISTRY CONDITION SEARCH

Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
COMPLETED
Registry last update
2022-10-10

This randomized phase II trial studies how well intravenous (IV) chemotherapy or oral chemotherapy works in treating patients with previously untreated stage III-IV human immunodeficiency virus (HIV)-associated non-Hodgkin lymphoma. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone, lomustine, etoposide, and procarbazine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Overall Survival

→

outcome · POSTED

Overall Response Rate

→

outcome · POSTED

Progression-free Survival

→

outcome · POSTED

Participants Who Experienced an Adverse Event

→

outcome · POSTED

Number of Patients Who Complete Treatment

→

outcome · POSTED

Proportion of Patients Who Are Adherent to Antiretroviral Therapy

→

outcome · POSTED

Proportion of Patients Who Are Adherent to Chemotherapy

→

outcome · POSTED

Change in Absolute CD4 Count From Baseline to Post-treatment

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Ability to understand and the willingness to provide written informed consent to participate * Adults, 18 years of age or older; date of birth should be determined based on the best possible information or source documentation available * HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or confirmed by HIV-1 antigen or plasma HIV-1 ribonucleic acid (RNA) viral load \> 1,000 copies/mL * NOTE: the term "licensed" refers to a United States (U.S.) Food and Drug Administration (FDA)-approved kit or for sites located in countries other than the United States, a kit that has been certified or licensed by an oversight body within that country and validated internally * WHO (World Health Organization) and CDC (Centers for Disease Control and Prevention) guidelines mandate that confirmation of the initial test result must use a test that is different from the one used for the initial assessment; a reactive initial rapid test should be confirmed by either another type of rapid assay or an E/CIA that is based on a different antigen preparation and/or different test principle (e.g., indirect versus competitive), or a Western blot or a plasma HIV-1 RNA viral load * Biopsy-proven, measurable or assessable systemic NHL that has been confirmed by an AIDS Malignancy Clinical Trial Consortium (AMC)-approved site pathologist; if a hard copy of the pathology report is unavailable at the time of enrollment, a verbal report by the pathologist confirming the diagnosis must be documented in the medical chart * Pathology slides from tumor tissue obtained by surgical excision or core biopsy must be reviewed by the designated site pathologist, or backup pathologist, prior to study entry; confirmation of the diagnosis must be documented by the AMC-approved pathologist prior to study entry; please reference the AMC-068 Manual of Procedures (MOP) for further instructions on documenting the diagnosis; the site pathologist for NHL must be approved through the AMC's external quality assessment (EQA) process * Participants must have fifteen blank(unstained) slides or a diagnostic tissue block must be available for central pathology review by the AMC Core Pathology Laboratory * Eastern Cooperative Oncology Group (ECOG) performance status of 0-3 * Participants must have an estimated life expectancy of \> 6 weeks * White blood cells (WBC) \>= 3,000 cells/uL (3.0 x 10\^9 L) or * Absolute granulocytes \>= 1500 cells/uL (1.5 x 10\^9 L) * Platelets \>= 100,000 cells/uL (75 x 10\^9 L) * Hemoglobin \> 8 g/dL (5.0 mmol/L) * Patients may enroll with lower hematologic values, if bone marrow involvement is documented; in this case, patients should be transfused to hemoglobin \> 8 g/dL * Serum creatinine \< 3.0 mg/dL (265.2 umol/L) * Total bilirubin =\< 1.5 institutional upper limit of normal (ULN), unless elevated secondary to lymphomatous involvement of liver or biliary system, or due to other HIV medications (e.g., indinavir, tenofovir, or atazanavir); if secondary to lymphomatous involvement, an initial upper limit of total bilirubin 5 mg/dL (85.5 uM/L) should be utilized - for direct bilirubin \> 1.2 mg/dL (20.5 uM/L) * Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =\< 2.5 institutional ULN (unless elevated secondary to lymphomatous involvement of the liver) * Participants must have a lumbar puncture with negative cerebral spinal fluid cytology within 6 weeks prior to enrollment; participants must be without evidence for central nervous system (CNS) lymphoma on neurological exam and have no radiographic evidence (if radiographic studies are done) of CNS lymphoma (inclusive of parenchymal, vitreal, or leptomeningeal involvement) * Participants must not have had any prior chemotherapy or radiation therapy and no more than 10 days of corticosteroids in the preceding 30 days prior to enrollment * All participants must be prescribed combination antiretroviral therapy with the goal of virological suppression using an acceptable regimen that adheres to national guidelines for treatment of HIV infection; non-suppressed, treatment experienced patients, defined as patients with a viral load \> 400 copies/mL who have been on antiretroviral therapy for more than 4 months can be enrolled if an alternative antiretroviral therapy (ART) regimen is available that includes at least two ART drugs that, in the opinion of the site investigator, are expected to have activity based on genotypic testing (if available) and treatment history; patients are not allowed to receive zidovudine (azidothymidine \[AZT\]) as part of concurrent chemotherapy and ART regimen, since it is myelosuppressive; zidovudine may be discontinued and substituted as clinically indicated prior to or at the time of enrollment. * Participants of childbearing potential, defined as a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months), must have a pregnancy test within 7 days prior to enrollment and agree to use an effective form of contraception (e.g., barrier contraception, highly effective hormonal contraception) * Participants are allowed to have an active infection(s) for which they are receiving drug treatment provided the clinical status is judged to be stable and survival is estimated to be at least 6 weeks * Participants must, in the opinion of the investigatory, be capable of complying with the protocol * Participants must be able to take oral medications * Participants must have a CD4 count performed within 30 days of enrollment Exclusion Criteria: * Inability to provide informed consent * A medical or psychiatric illness that precludes ability to give informed consent or is likely to interfere with the ability to comply with the protocol stipulations * Participants with circumstances that will not permit completion of the study or required follow-up; for instance, if travel to and from treatment site is an issue * Pregnant or breastfeeding * Inability to swallow oral medications
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients receive CHOP chemotherapy comprising cyclophosphamide IV on day 1, doxorubicin hydrochloride IV on day 1, vincristine sulfate IV on day 1, and prednisone PO on days 1-5. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Drug: cyclophosphamide
    2. Drug: doxorubicin hydrochloride
    3. Drug: vincristine sulfate
    4. Drug: prednisone
    5. Other: laboratory biomarker analysis
    label
    Arm I (CHOP)
    type
    ACTIVE_COMPARATOR
  2. description
    Patients receive lomustine PO QD on day 1 (courses 1 and 3 only), etoposide PO QD on days 1-3, cyclophosphamide PO QD on days 22-26, and procarbazine hydrochloride PO QD on days 22-26. Treatment repeats every 6 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Drug: lomustine
    2. Drug: etoposide
    3. Drug: cyclophosphamide
    4. Drug: procarbazine hydrochloride
    5. Other: laboratory biomarker analysis
    label
    Arm II (oral chemotherapy)
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Arm I (CHOP)
    description
    Given IV
    name
    cyclophosphamide
    other Names
    1. CPM
    2. CTX
    3. Cytoxan
    4. Endoxan
    5. Endoxana
    type
    DRUG
  2. arm Group Labels
    1. Arm I (CHOP)
    description
    Given IV
    name
    doxorubicin hydrochloride
    other Names
    1. ADM
    2. ADR
    3. Adria
    4. Adriamycin PFS
    5. Adriamycin RDF
    type
    DRUG
  3. arm Group Labels
    1. Arm I (CHOP)
    description
    Given IV
    name
    vincristine sulfate
    other Names
    1. leurocristine sulfate
    2. VCR
    3. Vincasar PFS
    type
    DRUG
  4. arm Group Labels
    1. Arm I (CHOP)
    description
    Given PO
    name
    prednisone
    other Names
    1. DeCortin
    2. Deltra
    type
    DRUG
  5. arm Group Labels
    1. Arm II (oral chemotherapy)
    description
    Given PO
    name
    lomustine
    other Names
    1. Belustine
    2. CCNU
    3. CeeNU
    type
    DRUG
  6. arm Group Labels
    1. Arm II (oral chemotherapy)
    description
    Given PO
    name
    etoposide
    other Names
    1. EPEG
    2. VP-16
    3. VP-16-213
    type
    DRUG
  7. arm Group Labels
    1. Arm II (oral chemotherapy)
    description
    Given PO
    name
    cyclophosphamide
    other Names
    1. CPM
    2. CTX
    3. Cytoxan
    4. Endoxan
    5. Endoxana
    type
    DRUG
  8. arm Group Labels
    1. Arm II (oral chemotherapy)
    description
    Given PO
    name
    procarbazine hydrochloride
    other Names
    1. Ibenzmethyzin
    2. Matulane
    3. MIH
    4. Natulan
    5. PCB
    type
    DRUG
  9. arm Group Labels
    1. Arm I (CHOP)
    2. Arm II (oral chemotherapy)
    description
    Correlative studies
    name
    laboratory biomarker analysis
    type
    OTHER
Study design
allocation
RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
7
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Proportion of participants who survived 2 years
    measure
    Overall Survival
    time Frame
    Up to 24 months
  2. description
    Overall response is complete or partial response as defined by response definitions of the 2014 International Conference on Malignant Lymphoma Imaging Working Group (i.e. Lugano classification). Complete response is the disappearance of all lesions with no new lesions detected. Partial response is \>=50% decrease in the sum of the perpendicular diameters of up to 6 target measurable nodes and extranodal sites and no new sites of disease.
    measure
    Overall Response Rate
    time Frame
    Up to 24 months
  3. description
    Proportion of participants who survived without disease progression at 2 years
    measure
    Progression-free Survival
    time Frame
    Up to 24 months
  4. description
    Number of participants who experienced an adverse event
    measure
    Participants Who Experienced an Adverse Event
    time Frame
    Up to 24 months
  5. description
    Number of patients who complete chemotherapy treatment.
    measure
    Number of Patients Who Complete Treatment
    time Frame
    Up to 18 weeks
  6. description
    Number of patients who did not miss any of their doses of antiretroviral therapy
    measure
    Proportion of Patients Who Are Adherent to Antiretroviral Therapy
    time Frame
    Up to 24 months
  7. description
    Patients who did not miss any doses of chemotherapy
    measure
    Proportion of Patients Who Are Adherent to Chemotherapy
    time Frame
    Up to 18 weeks
  8. description
    Change in absolute CD4 count from baseline to post-treatment (visit 6)
    measure
    Change in Absolute CD4 Count From Baseline to Post-treatment
    time Frame
    From baseline to 18 weeks
Full study description
brief Summary
This randomized phase II trial studies how well intravenous (IV) chemotherapy or oral chemotherapy works in treating patients with previously untreated stage III-IV human immunodeficiency virus (HIV)-associated non-Hodgkin lymphoma. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone, lomustine, etoposide, and procarbazine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells
detailed Description
PRIMARY OBJECTIVES: I. To compare the efficacy of standard cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone (CHOP) and an oral chemotherapy regimen for acquired immune deficiency syndrome (AIDS)-related (AR)-non-Hodgkin lymphoma (NHL) in sub-Saharan Africa with respect to overall survival (OS). SECONDARY OBJECTIVES: I. To compare the objectives response rate (ORR) of persons randomized to CHOP and oral chemotherapy. II. To compare the progression free survival (PFS) of persons randomized to CHOP and oral chemotherapy. III. To compare the safety and tolerance of persons randomized to CHOP and oral chemotherapy. TERTIARY OBJECTIVES: I. To describe the rates of completion of therapy of persons randomized to CHOP and oral chemotherapy. II. To describe adherence to chemotherapy of persons randomized to CHOP and oral chemotherapy. III. To describe adherence to antiretroviral therapy of persons randomized to CHOP and oral chemotherapy. IV. To describe the effects of therapy on HIV control, as measured by cluster of differentiation (CD)4 counts and HIV viral load. V. To investigate correlates of survival. OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients receive CHOP chemotherapy comprising cyclophosphamide intravenously (IV) on day 1, doxorubicin hydrochloride IV on day 1, vincristine sulfate IV on day 1, and prednisone orally (PO) on days 1-5. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. ARM II: Patients receive lomustine PO once daily (QD) on day 1 (courses 1 and 3 only), etoposide PO QD on days 1-3, cyclophosphamide PO QD on days 22-26, and procarbazine hydrochloride PO QD on days 22-26. Treatment repeats every 6 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 3, 6, 12, 18, and 24 months.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-e5babb0b5fa79a724504
      requested nct id
      NCT01775475
      primary nct id
      NCT01775475
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      a8469a8cca20a75ce4fa980eaab4ff20f62c99f2a2e732f1bd42590d1d5dbe14
      payload sha256
      228d5834572f86c7f298174b97200346e15ec46fc7e8308aeb18647d8a103ee2
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-e5babb0b5fa79a724504
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT01775475
      occurrences
      1. context exact
        NCT01775475
        end
        11
        exact text
        NCT01775475
        start
        0
      offset unit
      unicode_code_points
      query cond
      AIDS-Related Lymphoma
      query disease state id
      ds-aids-related-lymphoma
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-aids-related-lymphoma-000.json
      source file sha256
      a8469a8cca20a75ce4fa980eaab4ff20f62c99f2a2e732f1bd42590d1d5dbe14
      source json pointer
      /studies/5/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      47d7142d83569c136063cbefdb8837cbef2289a788e5bbc78119427bee402569

    Preserved source evidence · Not medical advice